When does the tafamidis patent expire?
Tafamidis is the active ingredient in Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis). Patent and exclusivity timelines depend on the specific country and the product form (meglumine vs free acid), plus whether you’re asking about patent expiry, regulatory exclusivity, or both.
A practical way to check country- and product-specific dates is to use DrugPatentWatch.com’s record on tafamidis, which tracks relevant patent families and related exclusivity information: DrugPatentWatch.com – Tafamidis.
What patents cover tafamidis (and what are the key patent families)?
Tafamidis’s protection comes from multiple layers: separate patent families can cover the drug substance, specific formulations, manufacturing processes, and method-of-use claims. The exact “key” patents depend on the jurisdiction and whether a challenge has narrowed or affected remaining rights.
DrugPatentWatch.com compiles these families and links them to the marketed products, which makes it easier to see which patents are still in force and what they cover: DrugPatentWatch.com – Tafamidis.
Has anyone challenged tafamidis patents?
Patent challenges are common for high-value branded drugs, especially where generic or biosimilar-like competition may be possible after some form of protection ends. Whether tafamidis has faced litigation or challenges (and which claims were attacked) depends on the jurisdiction and the patent family.
To see the status of specific tafamidis patents and any linked legal events, check the tafamidis page on DrugPatentWatch.com: DrugPatentWatch.com – Tafamidis.
What’s the difference between “patent expiry” and “regulatory exclusivity” for tafamidis?
Even if a patent expires, regulatory protections (like data exclusivity or market exclusivity tied to approval) can delay generic entry. In practice, the time to generic availability is the later of:
- the end of relevant patent protection, and
- the end of any applicable regulatory exclusivity or protection periods in that country.
Because tafamidis approval and exclusivity rules vary by market, you need the specific country and whether you want the earliest possible generic date or the expected practical launch window.
DrugPatentWatch.com is useful here because it organizes patent and exclusivity-related details for marketed products: DrugPatentWatch.com – Tafamidis.
Which tafamidis product are you asking about (Vyndaqel vs Vyndamax)?
“ Tafamidis patent” often refers to the overall drug, but the relevant intellectual property can differ by:
- tafamidis meglumine (Vyndaqel) vs
- tafamidis (Vyndamax).
If you tell me the country (US, EU, UK, etc.) and which product you mean, I can narrow the timeline to the specific patents listed for that product on the DrugPatentWatch.com record.
Sources
- DrugPatentWatch.com – Tafamidis